Beyond Cold Fingers: A Practical Approach to the Management of Raynaud’s Phenomenon
Abstract
RP is far more than a benign inconvenient reaction to cold exposure or a cosmetic concern; particularly in its secondary form, it can be associated with substantial morbidity. Early distinction between primary and secondary disease is paramount, as SRP may herald serious systemic pathology that extends well beyond the digital vasculature. Effective management requires a stepwise approach guided by disease subtype, severity, and associated comorbidities. This approach begins with comprehensive lifestyle modifications, progressing through evidence-based pharmacotherapy, and incorporating procedural or surgical interventions when necessary. Given their role in early recognition of connective tissue disease and cutaneous vasculopathy, dermatologists are uniquely positioned to identify, risk-stratify, and longitudinally manage patients with RP. A comprehensive and multidisciplinary treatment strategy addressing both vascular dysfunction and systemic disease remains central to reducing morbidity and preserving long-term function and quality of life.
References
Curtiss P, Svigos K, Schwager Z, Lo Sicco K, Franks AG Jr. Part I: Epidemiology, pathophysiology, and clinical considerations of primary and secondary Raynaud’s phenomenon. J Am Acad Dermatol. 2024;90(2):223 234. doi:10.1016/j.jaad.2022.06.1199
Curtiss P, Svigos K, Schwager Z, Lo Sicco K, Franks AG Jr. Part II: The treatment of primary and secondary Raynaud’s phenomenon. J Am Acad Dermatol. 2024;90(2):237-248. doi:10.1016/j.jaad.2022.05.067
Flavahan NA. A vascular mechanistic approach to understanding Raynaud phenomenon. Nat Rev Rheumatol. 2015;11(3):146-158. doi:10.1038/ nrrheum.2014.195
Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum. 2013;65(8):1953-1962. doi:10.1002/art.37988
Campbell PM, LeRoy EC. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum. 1975;4(4):351-368. doi:10.1016/0049 0172(75)90017-7
Bakst R, Merola JF, Franks AG Jr, Sanchez M. Raynaud’s phenomenon: pathogenesis and management. J Am Acad Dermatol. 2008;59(4):633-653. doi:10.1016/j. jaad.2008.06.004
Dolez PI, Vu-Khanh T. Gloves for protection from cold weather. In: Williams JT, ed. Textiles for Cold Weather Apparel. Cambridge: Woodhead Publishing; 2009. p.374-398.
Hayward JM, Holmes WF, Gooden BA. Cardiovascular responses in man to a stream of cold air. Cardiovasc Res. 1976;10(6):691-696. doi:10.1093/cvr/10.6.691
Hudson M, Lo E, Lu Y, Hercz D, Baron M, Steele R, et al. Cigarette smoking in patients with systemic sclerosis. Arthritis Rheum. 2011;63(1):230-238. doi:10.1002/ art.30071
Mohokum M, Hartmann P, Schlattmann P. The association of Raynaud syndrome with β-blockers: a meta-analysis. Angiology. 2012;63(7):535-540. doi:10.1177/000331971142861
Curtiss P, Cobos G, Lo Sicco K, Franks AG Jr. The Frisbee maneuver: a novel method to abort acute attacks of the Raynaud phenomenon. J Am Acad Dermatol. 2018;78(3):e61. doi:10.1016/j. jaad.2017.09.066
McIntyre DR. A maneuver to reverse Raynaud’s phenomenon of the fingers. JAMA. 1978;240(25):2760.
Freedman RR, Ianni P, Wenig P. Behavioral treatment of Raynaud’s disease. J Consult Clin Psychol. 1983;51(4):539-549. doi:10.1037/0022-006X.51.4.539
Rirash F, Tingey PC, Harding SE, Maxwell LJ, Tanjong Ghogomu E, Wells GA, et al. Calcium channel blockers for primary and secondary Raynaud’s phenomenon. Cochrane Database Syst Rev. 2017;12(12):CD000467. doi:10.1002/14651858.CD000467.pub2
Curtiss P, Schwager Z, Cobos G, Lo Sicco K, Franks AG Jr. A systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud’s phenomenon. J Am Acad Dermatol. 2018;78(6):1110-1118.e3. doi:10.1016/j. jaad.2018.01.043
Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud’s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis. 2013;72(10):1696-1699. doi:10.1136/annrheumdis-2012-202836
Hachulla E, Hatron PY, Carpentier P, Agard C, Chatelus E, Jego P, et al. Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann Rheum Dis. 2016;75(6):1009-1015. doi:10.1136/ annrheumdis-2014-207001
Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double blind, placebo-controlled trial. Ann Rheum Dis. 2011;70(1):32-38. doi:10.1136/ard.2010.130658
Jenkins SN, Neyman KM, Veledar E, Chen SC. A pilot study evaluating the efficacy of botulinum toxin A in the treatment of Raynaud phenomenon. J Am Acad Dermatol. 2013;69(5):834-835. doi:10.1016/j. jaad.2013.06.029
Curtiss P, Schwager Z, Lo Sicco K, Franks AG Jr. The clinical effects of L-arginine and asymmetric dimethylarginine: implications for treatment in secondary Raynaud’s phenomenon. J Eur Acad Dermatol Venereol. 2019;33(3):497-503. doi:10.1111/ jdv.15180